NEW YORK (GenomeWeb News) – OncoMethylome Sciences will supply Laboratory Corporation of America with reagents used in a stool-based test for colorectal cancer, the Belgian company said today.
OncoMethylome will sell to Labcorp reagents used to detect methylation of the Vimentin DNA marker with Methylation-Specific PCR, which can be used to detect colorectal cancer through stool-based tests from patients who are traditionally non-compliant to colorectal screening. OncoMethylome said that it will qualify for milestones linked to LabCorp’s sales of the reagents.
OncoMethylome’s gene methylation tests are used to detect early-stage cancer, predict patient response to therapy, and to predict the chance of a cancer’s recurrence.
Financial terms of the agreement were not released.